These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 22240299

  • 41. Longitudinal analysis of performance of estimated glomerular filtration rate as renal function declines in chronic kidney disease.
    Lee D, Levin A, Roger SD, McMahon LP.
    Nephrol Dial Transplant; 2009 Jan; 24(1):109-16. PubMed ID: 18755849
    [Abstract] [Full Text] [Related]

  • 42. [Chemotherapy of invasive bladder cancer].
    Kotake T.
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
    [Abstract] [Full Text] [Related]

  • 43. [Assessment of renal function according to the NHG protocol 'Diabetes mellitus type 2': risk of overestimating the number of diabetes patients with renal dysfunction].
    Bilo HJ, Logtenberg SJ, Dikkeschei LD, Kleefstra N, Wolffenbuttel BH.
    Ned Tijdschr Geneeskd; 2007 May 05; 151(18):1024-8. PubMed ID: 17508689
    [Abstract] [Full Text] [Related]

  • 44. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
    Yamauchi T, Hida S, Ooishi K, Okada K, Yoshida O.
    Hinyokika Kiyo; 1985 Jul 05; 31(7):1093-104. PubMed ID: 2414981
    [Abstract] [Full Text] [Related]

  • 45. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, Bokemeyer C.
    Anticancer Res; 2000 Jul 05; 20(5C):3767-73. PubMed ID: 11268452
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
    Ochiai K, Isonishi S, Kimura E, Yokoyama S, Sasaki H, Arihiro T, Terashima Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan 05; 43(1):19-25. PubMed ID: 1997612
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. [Chemotherapy of metastatic urothelial carcinoma].
    Kihara K, Sakuramoto T, Washizuka M, Kawai T, Ogawa M.
    Gan To Kagaku Ryoho; 1982 Nov 05; 9(11):2046-7. PubMed ID: 6892194
    [Abstract] [Full Text] [Related]

  • 53. Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma.
    Hosohata K, Washino S, Kubo T, Natsui S, Fujisaki A, Kurokawa S, Ando H, Fujimura A, Morita T.
    Toxicology; 2016 Jun 01; 359-360():71-5. PubMed ID: 27317936
    [Abstract] [Full Text] [Related]

  • 54. Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.
    Ogawa T, Niho S, Nagai S, Kojima T, Nishimura Y, Ohe Y, Kondo N, Yamaguchi T, Endo K, Izumi K, Minami H.
    Int J Clin Oncol; 2013 Dec 01; 18(6):977-82. PubMed ID: 23053402
    [Abstract] [Full Text] [Related]

  • 55. Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer.
    Kikuchi T, Akamatsu H, Mori K, Tanaka A, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Nakanishi M, Ueda H, Yamamoto N.
    Respir Investig; 2016 Nov 01; 54(6):479-483. PubMed ID: 27886861
    [Abstract] [Full Text] [Related]

  • 56. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y.
    Cancer Chemother Pharmacol; 1996 Nov 01; 39(1-2):131-7. PubMed ID: 8995510
    [Abstract] [Full Text] [Related]

  • 57. [Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma].
    Li X, Sheng XN, Chi ZH, Cui CL, Si L, Mao LL, Tang BX, Lian B, Wang X, Yan XQ, Li SM, Bai X, Zhou L, Kong Y, Dai J, Guo J.
    Zhonghua Yi Xue Za Zhi; 2018 Aug 28; 98(32):2574-2578. PubMed ID: 30220142
    [Abstract] [Full Text] [Related]

  • 58. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
    Hinai Y, Motoyama S, Niioka T, Miura M.
    J Clin Pharm Ther; 2013 Dec 28; 38(6):498-503. PubMed ID: 24102360
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?
    Bennis Y, Savry A, Rocca M, Gauthier-Villano L, Pisano P, Pourroy B.
    Int J Clin Pharm; 2014 Apr 28; 36(2):420-9. PubMed ID: 24435159
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.